CoChat
Sign Up
Cited by 32Muscle Physiology and DisordersNutrition and Health in AgingChronic Obstructive Pulmonary Disease (COPD) Research

MuRF-1 and Atrogin-1 Protein Expression and Quadriceps Fiber Size and Muscle Mass in Stable Patients with COPD

Open access
Natanek, Samantha A., Riddoch-Contreras, Joanna, Marsh, Gemma S., Hopkinson, Nicholas S., Moxham, John, Man, William D.-C., Kemp, Paul R., Polkey, Michael I.·2013·COPD: Journal of Chronic Obstructive Pulmonary Disease
DOI 10.3109/15412555.2013.781577PMC PMC4002632
Open this paper in CoChat — free accountOpen PDF

Abstract

INTRODUCTION: Animal studies demonstrate the importance of the E3 ubiquitin ligases, Muscle RING-Finger Protein 1 (MuRF-1) and atrogin-1, in muscle protein degradation during acute muscle atrophy. Small clinical studies suggest MuRF-1 and atrogin-1 expression in the quadriceps muscle is also increased in stable patients with Chronic Obstructive Pulmonary Disease compared to controls. However, it remains unclear whether these ligases have a role in maintaining a muscle-wasted state in COPD patients. METHODS: 32 stable COPD patients (16 with a low fat-free mass index (FFMI), 16 with a normal FFMI) and 15 controls underwent lung function and quadriceps strength tests and a percutaneous quadriceps biopsy. Quadriceps MuRF-1 and atrogin-1 protein were quantified with western blotting. Quadriceps fiber cross-sectional area (CSA) and fiber proportions were determined by immunohistochemistry on muscle sections. MuRF-1 and atrogin-1 levels were compared between COPD patients with and without a low FFMI, and between patients and controls, and correlations between MuRF-1 and atrogin-1 levels and quadriceps fiber CSA in the patients were investigated. RESULTS: Atrogin-1 protein levels were lower in patients than controls, but similar in patients with a low and normal FFMI. MuRF-1 levels did not differ between any groups. MuRF-1 and atrogin-1 levels were not associated with quadriceps fiber CSA or quadriceps strength in patients. CONCLUSIONS: Chronic upregulation of ubiquitin ligases was not evident in the quadriceps muscle of stable COPD patients with a low muscle mass. This does not exclude the possibility of transient increases in ubiquitin ligases during acute catabolic episodes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/15412555.2013.781577

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some studies have failed to report a significant difference in atrogenes between COPD patients and healthy subjects, possibly due to timing of assessment.

    “Of note, some studies have failed to report a significant difference between COPD patients and healthy subjects [166], possibly due to the timing of the assessment.”

    From Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting (2023) · cites this paper as [166]

    The Results report no significant difference in MuRF-1 protein between COPD patients and controls, but atrogin-1 protein was significantly lower in the COPD group. The Discussion considers measurement timing as a possible reason ubiquitin-ligase levels may not be elevated in stable patients; it does not establish timing as the cause of the MuRF-1 result. Thus the claim is supported for MuRF-1, not for both atrogenes. (LLM, conf=0.89)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 36

  1. [1]Seymour JM Spruit MA Hopkinson NS Sathyapala SA Man WD Jackson A Gosker HR Schols AM Moxham J Polkey MI et al The prevalence of quadriceps weakness in COPD and the relationship with disease severity Eur Respir J 2010 36 81 88 19897554 PMC3039205
  2. [2]Marquis K Debigare R Lacasse Y LeBlanc P Jobin J Carrier G Maltais F Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 2002 166 809 813 12231489
  3. [3]Swallow EB Reyes D Hopkinson NS Man WD Porcher R Cetti EJ Moore AJ Moxham J Polkey MI Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease Thorax 2007 62 115 120 17090575 PMC2111256
  4. [4]Bodine SC Latres E Baumhueter S Lai VK Nunez L Clarke BA Poueymirou WT Panaro FJ Na E Dharmarajan K et al Identification of ubiquitin ligases required for skeletal muscle atrophy Science 2001 294 1704 1708 11679633
  5. [6]Li YP Chen Y John J Moylan J Jin B Mann DL Reid MB Tnf-alpha acts via p38 mapk to stimulate expression of the ubiquitin ligase atrogin1/mafbx in skeletal muscle FASEB J 2005 19 362 370 15746179 PMC3099533
  6. [7]Agusti A Morla M Sauleda J Saus C Busquets X Nf-kappab activation and inos upregulation in skeletal muscle of patients with copd and low body weight Thorax 2004 59 483 487 15170030 PMC1747038
  7. [8]Mercken EM Hageman GJ Langen RC Wouters EF Schols AM Decreased exercise-induced expression of nuclear factor-kappab-regulated genes in muscle of patients with copd Chest 2011 139 337 346 20688919
  8. [10]Riddoch-Contreras J George T Natanek SA Marsh GS Hopkinson NS Tal-Singer R Kemp P Polkey MI P38 mitogen-activated protein kinase is not activated in the quadriceps of patients with stable chronic obstructive pulmonary disease COPD 2012 142 150 22409248
  9. [11]Lemire BB Debigare R Dube A Theriault ME Cote CH Maltais F Mapk signalling in the quadriceps of patients with chronic obstructive pulmonary disease J Appl Physiol 2012 113 1 159 166 22518834
  10. [12]Doucet M Russell AP Leger B Debigare R Joanisse DR Caron MA LeBlanc P Maltais F Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 2007 176 261 269 17478621
  11. [13]Plant PJ Brooks D Faughnan M Bayley T Bain J Singer L Correa J Pearce D Binnie M Batt J Cellular markers of muscle atrophy in chronic obstructive pulmonary disease (COPD) Am J Respir Cell Mol Biol 2010 424 461 471 19520920
  12. [14]Schols AM Soeters PB Dingemans AM Mostert R Frantzen PJ Wouters EF Prevalence and characteristics of nutritional depletion in patients with stable copd eligible for pulmonary rehabilitation Am Rev Respir Dis 1993 147 1151 1156 8484624
  13. [15]Pauwels RA Buist AS Calverley PM Jenkins CR Hurd SS Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Nhlbi/who global initiative for chronic obstructive lung disease (GOLD) workshop summary Am J Respir Crit Care Med 2001 163 1256 1276 11316667
  14. [16]Miller MR Hankinson J Brusasco V Burgos F Casaburi R Coates A Crapo R Enright P van der Grinten CP Gustafsson P et al Standardisation of spirometry Eur Respir J 2005 26 319 338 16055882
  15. [17]Wanger J Clausen JL Coates A Pedersen OF Brusasco V Burgos F Casaburi R Crapo R Enright P van der Grinten CP et al Standardisation of the measurement of lung volumes Eur Respir J 2005 26 511 522 16135736
  16. [18]Macintyre N Crapo RO Viegi G Johnson DC van der Grinten CP Brusasco V Burgos F Casaburi R Coates A Enright P et al Standardisation of the single-breath determination of carbon monoxide uptake in the lung Eur Respir J 2005 26 720 735 16204605
  17. [19]Pitta F Troosters T Spruit MA Decramer M Gosselink R Activity monitoring for assessment of physical activities in daily life in patients with chronic obstructive pulmonary disease Arch Phys Med Rehabil 2005 86 1979 1985 16213242
  18. [20]Steiner MC Barton RL Singh SJ Morgan MD Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD Eur Respir J 2002 19 626 631 11998990
  19. [21]Edwards RH Young A Hosking GP Jones DA Human skeletal muscle function: Description of tests and normal values Clin Sci Mol Med 1977 52 283 290 844260
  20. [22]Polkey MI Kyroussis D Hamnegard CH Mills GH Green M Moxham J Quadriceps strength and fatigue assessed by magnetic stimulation of the femoral nerve in man Muscle Nerve 1996 19 549 555 8618551
  21. [23]Ats statement: Guidelines for the six-minute walk test Am J Respir Crit Care Med 2002 166 111 117 12091180
  22. [24]Hopkinson NS Man WD Dayer MJ Ross ET Nickol AH Hart N Moxham J Polkey MI Acute effect of oral steroids on muscle function in chronic obstructive pulmonary disease Eur Respir J 2004 24 137 142 15293616
  23. [25]J B Percutaneous needle biopsy of skeletal muscle in physiological and clinical research Scand J Clin Lab Invest 1975 35 609 616 1108172
  24. [26]Russell AP Wadley G Hesselink MK Schaart G Lo S Leger B Garnham A Kornips E Cameron-Smith D Giacobino JP et al Ucp3 protein expression is lower in type i, iia and iix muscle fiber types of endurance-trained compared to untrained subjects Pflugers Arch 2003 445 563 569 12634927
  25. [28]Natanek S.A Gosker HR Slot IGM Marsh GS Hopkinson NS Man WD-C Tal-Singer RM Moxham J Kemp PR Schols AMWJ et al Heterogeneity of quadriceps muscle phenotype in chronic obstructive pulmonary disease (copd); implications for stratified medicine? Muscle Nerve 2012; in press still PMID 23553751 23553751
  26. [29]Rennie MJ Muscle protein turnover and the wasting due to injury and disease Br Med Bull 1985 41 257 264 3896381
  27. [30]Rennie MJ Edwards RH Emery PW Halliday D Lundholm K Millward DJ Depressed protein synthesis is the dominant characteristic of muscle wasting and cachexia Clin Physiol 1983 3 387 398 6357592
  28. [31]Rennie MJ Harrison R Effects of injury, disease, and malnutrition on protein metabolism in man. Unanswered questions Lancet 1984 1 323 325 6141389
  29. [32]Petersen AM Magkos F Atherton P Selby A Smith K Rennie MJ Pedersen BK Mittendorfer B Smoking impairs muscle protein synthesis and increases the expression of myostatin and mafbx in muscle Am J Physiol Endocrinol Metab 2007 293 E843 848 17609255
  30. [34]Rabinovich RA Vilaro J Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients Curr Opin Pulm Med 2010 16 123 133 20071991 PMC2920417
  31. [35]de Boer MD Selby A Atherton P Smith K Seynnes OR Maganaris CN Maffulli N Movin T Narici MV Rennie MJ The temporal responses of protein synthesis, gene expression and cell signalling in human quadriceps muscle and patellar tendon to disuse J Physiol 2007 585 241 251 17901116 PMC2375459
  32. [37]Rennie MJ Smith K Watt PW Measurement of human tissue protein synthesis: An optimal approach Am J Physiol 1994 266 E298 307 8166250
  33. [38]Hopkinson NS Tennant RC Dayer MJ Swallow EB Hansel TT Moxham J Polkey MI A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease Respir Res 2007 8 25 17355636 PMC1832189
  34. [39]Lewis A Riddoch-Contreras J Natanek SA Donaldson A Man WD Moxham J Hopkinson NS Polkey MI Kemp PR Downregulation of the serum response factor/mir-1 axis in the quadriceps of patients with COPD Thorax 2012 67 26-34 21998125 PMC3240776
  35. [40]Donaldson AV Natanek SA Man WD-C Kemp PR Polkey MI Increased skeletal muscle-specific microrna-1 in the blood of COPD patients Thorax 2012 65 A25 PMC3841809 23814167
  36. [41]Spruit MA Gosselink R Troosters T Kasran A Gayan-Ramirez G Bogaerts P Bouillon R Decramer M Muscle force during an acute exacerbation in hospitalised patients with copd and its relationship with cxcl8 and igf-i Thorax 2003 58 752 756 12947130 PMC1746817

Cited by

Sorted by citations

Authors
Natanek, S. A., Riddoch-Contreras, J., Marsh, G. S., Hopkinson, N. S., Moxham, J., Man, W. D.-C., Kemp, P. R., & Polkey, M. I.
Affiliations
  • Royal Brompton & Harefield NHS Foundation Trust (GB)
  • Imperial College London (GB)
Corresponding author
Polkey, Michael I.
ORCID
Venue
COPD: Journal of Chronic Obstructive Pulmonary Disease
Publisher
Informa UK Limited
Published
2013-07-11
Volume
10
Issue
5
Pages
618-624
ISSN
  • 1541-2555 (ISSN-L)
  • 1541-2563
DOI
10.3109/15412555.2013.781577
PMC
PMC4002632
OpenAlex
W2167664180
Cited by
32
References
4
Citations by year
2026: 1 · 2025: 4 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 2 · 2014: 4
FWCI
1.64
Type
journal article
Language
en
Open access
Locations
  • COPD Journal of Chronic Obstructive Pulmonary Disease (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion, other-oa)
Funders
National Institute for Health and Care Research (DHCS/07/07/009, CTF-01-12-04)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
MuRF1, atrogin-1, E3 ubiquitin ligase, chronic obstructive pulmonary disease, muscle atrophy, muscle protein degradation, quadriceps, muscle fiber cross-sectional area, fat-free mass index, muscle mass, muscle strength
MeSH terms
Tripartite Motif Proteins, Aged, Female, Humans, Male, Middle Aged, Muscle Proteins, Muscular Atrophy, Organ Size, Severity of Illness Index, Case-Control Studies, Muscle Fibers, Skeletal, Pulmonary Disease, Chronic Obstructive, Ubiquitin-Protein Ligases, SKP Cullin F-Box Protein Ligases, Quadriceps Muscle

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review